Organic Chemical
Vigil Neuroscience’s Oral Alzheimer’s Candidate VG-3927 Shows Promising Phase 1 Results with Sanofi’s Strategic Support
Vigil Neuroscience, VG-3927, Alzheimer’s disease, Phase 1 clinical trial, Sanofi strategic investment, TREM2 agonist program, Microglia therapy
Revitalizing Maternal Health: Nonprofit Leverages Low-Dose Aspirin to Combat Preeclampsia Disparities
Preeclampsia, Maternal Health Equity, Low-Dose Aspirin, GAP—SPIRIN, Health Disparities, Black Maternal Health
FDA Adds Boxed Warning to Teva’s Copaxone and Generic Glatopa Due to Anaphylaxis Risk
FDA Boxed Warning, Anaphylaxis Risk, Copaxone, Glatopa, Glatiramer Acetate, Multiple Sclerosis (MS) Treatment, Allergic Reaction
Catalent and Galapagos Collaborate on Decentralized CAR-T Manufacturing; Kindeva Secures $129M Contract for Nerve Agent Antidote
Catalent, Galapagos, CAR-T therapy, Decentralized manufacturing, Non-Hodgkin lymphoma (NHL), Kindeva Drug Delivery, DuoDote, Nerve agent antidote, Strategic National Stockpile
Johnson & Johnson’s Darzalex and Spravato Achieve Milestones: Darzalex Leads Sales, Spravato Surpasses $1 Billion Revenue
Johnson & Johnson, Darzalex, Spravato, Pharmaceutical Sales, Multiple Myeloma, Depression Treatment, Revenue Milestones
J&J’s Spravato Surpasses $1 Billion in Revenue for 2024
J&J, Spravato, revenue, 2024, depression treatment, nasal spray
Trump’s Second Term: Mifepristone Battle Looms as Early Test of Abortion Stance
Mifepristone, abortion, Trump, second term, reproductive rights, FDA, Supreme Court
Boehringer Ingelheim’s Iclepertin Fails to Meet Primary and Secondary Endpoints in Phase III Schizophrenia Trials
Boehringer Ingelheim, iclepertin, schizophrenia, Phase III trials, cognitive impairment, CONNEX program
Novartis Secures Temporary Block on Generic Version of Entresto
Novartis, Entresto, generic version, MSN Pharmaceuticals, temporary block, heart failure drug
AstraZeneca’s Calquence Gains FDA Approval as First-Line Treatment for Mantle Cell Lymphoma
AstraZeneca, Calquence, acalabrutinib, BTK inhibitor, mantle cell lymphoma, first-line treatment, FDA approval